NICE recommends first licenced treatment for AL amyloidosis
European Pharmaceutical Review
FEBRUARY 29, 2024
NICE’s positive decision, which is detailed in the final appraisal document , follows an appeal against NICE’s original guidance from November 2022. The document highlighted that daratumumab in combination “increases the time until systemic AL amyloidosis gets worse compared with bortezomib plus cyclophosphamide and dexamethasone.”
Let's personalize your content